

[Chem. Pharm. Bull.]  
30(4)1481-1484(1982)

## Neurotropic and Psychotropic Agents. VII.<sup>1a)</sup> Synthesis and Pharmacological Properties of 2-(Alkoxyalkylamino)-3*H*-1,4-benzodiazepines

MASAAKI MATSUO, KIYOSHI TANIGUCHI, and IKUO UEDA\*

Central Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 1-6,  
2-chome, Kashima, Yodogawa-ku, Osaka 532, Japan

(Received July 8, 1981)

The synthesis and pharmacological properties of some 2-(alkoxyalkylamino)-3*H*-1,4-benzodiazepine derivatives (I and II) are described. Compounds I were prepared from the corresponding 2-methylthio-1,4-benzodiazepines and primary amines. Compounds II were prepared by alkylation of the corresponding 2-monoalkylamino-1,4-benzodiazepines with alkyl or alkoxyalkyl halides. The compounds (I and II) showed tranquilizing profiles like that of chlordiazepoxide in taming and anticonvulsant tests in mice.

**Keywords**—2-(alkoxyalkylamino)-3*H*-1,4-benzodiazepine; 2-monoalkylamino-3*H*-1,4-benzodiazepine; pharmacological test; taming effect in mice; anticonvulsant effect in mice

In the previous papers,<sup>1)</sup> we described the synthesis and pharmacological properties of 2-(2-dimethylaminoethylthio)-3*H*-1,4-benzodiazepine derivatives and 1-benzyloxymethyl-1,3-dihydro-1,4-benzodiazepin-2-one derivatives. In view of the pronounced central nervous system activities of these compounds, we thought it useful to study 2-(alkoxyalkylamino)-3*H*-1,4-benzodiazepines (I and II).

Compounds I were prepared from 7-chloro-5-(2-chlorophenyl)-2-methylthio-3*H*-1,4-benzodiazepine<sup>2)</sup> and the corresponding methoxyalkylamines according to the procedures described in the literature.<sup>3)</sup> 2-Dialkylamino-3*H*-1,4-benzodiazepines (II) were prepared by *N*-alkylation of 7-chloro-5-(2-chlorophenyl)-2-monoalkylamino-3*H*-1,4-benzodiazepines with corresponding alkyl or alkoxyalkyl halides in the presence of sodium hydride in *N,N*-dimethylformamide.<sup>4)</sup>






Fig. 1

The physical data for 2-dialkylamino derivatives (II) thus obtained are summarized, together with the reaction conditions, in Table I.

### Pharmacological Results

The 2-(alkoxyalkylamino) derivatives (I and II) prepared here were screened for usual central nervous system effects, taming and anticonvulsant activities, in laboratory animals according to the procedures described in the literature.<sup>5)</sup> Compounds I and II showed tranquilizing profiles essentially like that of chlordiazepoxide (Table II). The compounds tested were less active in the mice-taming test than chlordiazepoxide, while compounds I-1, II-1, II-2, II-4, II-5, and II-9 showed more potent anti-metrazole activity in mice than chlordi-

TABLE I. 2-Dialkylamino-3H-1,4-benzodiazepines (II)

Compd.	R <sub>1</sub>	-CH(CH <sub>2</sub> ) <sub>m</sub> OR <sub>3</sub>			Alkylating <sup>a)</sup> agent	Reaction time (°C) (h)	mp (°C) (Solvent) <sup>e)</sup>	Yield (%)	Formula	Analysis (%)		
		R <sub>2</sub>	R <sub>3</sub>	m						Calcd	Found	C
II-1	CH <sub>3</sub>	H	CH <sub>3</sub>	0	<sup>a)</sup>	111-112.5 (H-E)	38.4	C <sub>13</sub> H <sub>17</sub> Cl <sub>2</sub> N <sub>3</sub> O	59.68 (59.44)	4.73 4.68	11.60 11.47	
II-2	CH <sub>3</sub>	H	CH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>	0	<sup>b)</sup>	83.5-86.5 (H-CH-E)	42.1	C <sub>24</sub> H <sub>21</sub> Cl <sub>2</sub> N <sub>3</sub> O	65.76 (65.69)	4.83 4.75	9.59 9.71	
II-3	CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>	0	5 3/4	115.5-117.5 (H-E)	24.6	C <sub>23</sub> H <sub>23</sub> Cl <sub>2</sub> N <sub>3</sub> O	66.37 (66.48)	5.12 5.07	9.29 9.24	
II-4	CH <sub>3</sub>	H	CH <sub>3</sub>	1	5 1.0	112-115 (H-E)	70.3	C <sub>19</sub> H <sub>19</sub> Cl <sub>2</sub> N <sub>3</sub> O	60.65 (60.59)	5.09 5.04	11.17 11.26	
II-5	CH <sub>3</sub>	H	CH(CH <sub>3</sub> ) <sub>2</sub>	1	1 3.5	82.5-85 (H-P)	67.8	C <sub>21</sub> H <sub>23</sub> Cl <sub>2</sub> N <sub>3</sub> O	62.38 (62.40)	5.73 5.70	10.39 10.29	
II-6	CH <sub>3</sub>	H	CH <sub>3</sub>	2	<sup>a)</sup>	Oil	99.4	C <sub>20</sub> H <sub>21</sub> Cl <sub>2</sub> N <sub>3</sub> O	—	—	—	
II-7	CH <sub>2</sub> CH <sub>3</sub>	H	CH <sub>3</sub>	0	20 1.5	98.5-101 (H-E)	23.8	C <sub>19</sub> H <sub>19</sub> Cl <sub>2</sub> N <sub>3</sub> O	60.65 (60.53)	5.09 4.98	11.17 11.09	
II-8	CH(CH <sub>3</sub> ) <sub>2</sub>	H	CH <sub>3</sub>	0	5 1.5	159.5-161 (E)	23.1	C <sub>20</sub> H <sub>21</sub> Cl <sub>2</sub> N <sub>3</sub> O	61.54 (61.33)	5.42 5.45	10.77 10.54	
II-9		H	CH <sub>3</sub>	0	20 1.5	68-82 (P)	21.3	C <sub>20</sub> H <sub>19</sub> Cl <sub>2</sub> N <sub>3</sub> O	61.86 (61.70)	4.93 4.83	10.82 10.74	
II-10		H	CH <sub>3</sub>	0	5 2.0	144.5-146.5 (H-E)	4.6	C <sub>23</sub> H <sub>25</sub> Cl <sub>2</sub> N <sub>3</sub> O	64.19 (64.28)	5.86 5.71	9.76 9.83	

<sup>a)</sup> Reacted at 5°C for 1 h, then at 20°C for 1 h.

<sup>b)</sup> Reacted at 5°C for 20 min, then at 20°C for 20 min.

<sup>c)</sup> H, n-hexane; E, ethanol; CH, cyclohexane; P, petroleum ether.

<sup>d)</sup> A, R<sub>3</sub>O(CH<sub>2</sub>)<sub>m</sub>CHCl; B, (CH<sub>3</sub>)<sub>2</sub>CHOCH<sub>2</sub>CH<sub>2</sub>Br; C, CH<sub>3</sub>I.

R<sub>3</sub>

TABLE II. Pharmacological Activities of 2-(Alkoxyalkylamino)-7-chloro-5-(2-chlorophenyl)-3*H*-1,4-benzodiazepines (I and II) in Mice

Compd.	Taming activity Anti-fighting ED <sub>50</sub> (mg/kg <i>p.o.</i> )	Anticonvulsant activity Anti-metrazole ED <sub>50</sub> (mg/kg <i>p.o.</i> )
I-1	3.99	1.83
I-2	18.23	6.32
II-1	5.26	4.02
II-2	7.86	4.98
II-3	34.57	16.00
II-4	3.50	1.65
II-5	8.00	1.99
II-6	6.57	5.66
II-7	23.78	6.76
II-8	34.57	9.95
II-9	3.99	3.51
II-10	a)	a)
Chlordiazepoxide	0.57	5.22
Diazepam	0.23	1.17

a) ED<sub>50</sub> >125 mg/kg.

azepoxide. Thus, introduction of an alkoxyalkylamino group did not improve these activities and led to a significant decrease in taming activity.

#### Experimental<sup>6)</sup>

Solvents used were dried over molecular sieves 3A before use.

Benzyloxymethyl chloride,<sup>7a)</sup> 2-isopropoxyethyl bromide,<sup>7b)</sup> and 1-benzyloxyethyl chloride<sup>1a)</sup> were prepared by the methods described in the literature.

7-Chloro-5-(2-chlorophenyl)-2-monoalkylamino-3*H*-1,4-benzodiazepines were prepared according to the method described in the literature.<sup>3)</sup>

**7-Chloro-5-(2-chlorophenyl)-2-(2-methoxyethylamino)-3*H*-1,4-benzodiazepine (I-1)**—Compound I-1 was prepared from 7-chloro-5-(2-chlorophenyl)-2-methylthio-3*H*-1,4-benzodiazepine<sup>2)</sup> (66.8 g) and 2-methoxyethylamine (500 ml) according to the method described in the literature.<sup>3)</sup> Yield: 78.6%, mp 185–189°C (from EtOH). *Anal.* Calcd for C<sub>18</sub>H<sub>17</sub>Cl<sub>2</sub>N<sub>3</sub>O: C, 59.68; H, 4.73; N, 11.60. Found: C, 59.57; H, 4.72; N, 11.61.

**7-Chloro-5-(2-chlorophenyl)-2-(3-methoxypropylamino)-3*H*-1,4-benzodiazepine** was prepared by a similar method. Yield: 89.1%. mp 175.5–179°C (from CH<sub>3</sub>O(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>). *Anal.* Calcd for C<sub>19</sub>H<sub>19</sub>Cl<sub>2</sub>N<sub>3</sub>O: C, 60.65; H, 5.09; N, 11.17. Found: C, 60.64; H, 5.10; N, 11.16.

**7-Chloro-5-(2-chlorophenyl)-2-(*N*-benzyloxymethyl-*N*-methylamino)-3*H*-1,4-benzodiazepine (II-2)**—A 50% NaH dispersion in mineral oil (2.03 g) was added in small portions to a suspension of 7-chloro-5-(2-chlorophenyl)-2-methylamino-3*H*-1,4-benzodiazepine<sup>8)</sup> (10.0 g) in dry dimethylformamide (DMF) (45 ml) with stirring under ice-H<sub>2</sub>O cooling. After 40 min of stirring, benzyloxymethyl chloride (6.64 g) was added to the resulting solution at 5°C. After the mixture had been stirred for 20 min at 5°C, additional benzyloxymethyl chloride (1.30 g) was added with stirring. After being allowed to warm up to 20°C and then being stirred for 20 min, the mixture was poured into ice-H<sub>2</sub>O and extracted with AcOEt. The extract was washed with brine, dried over MgSO<sub>4</sub> and concentrated *in vacuo*. The resulting residue was subjected to column chromatography on alumina with benzene. The first eluate gave II-2 (5.8 g).

Compounds prepared are summarized, together with the reaction conditions, in Table I.

**Acknowledgement** The authors wish to thank Dr. S. Uchida and his colleagues of the pharmacological division for the pharmacological testing of the compounds prepared.

#### References and Notes

- 1) a) Part VI: T. Kishimoto, M. Matsuo, and I. Ueda, *Chem. Pharm. Bull.*, **30**, 1477 (1982); b) M. Matsuo, K. Taniguchi, and I. Ueda, *ibid.*, **30**, 1141 (1982) as Part IV of our studies.

- 2) J.B. Hester, Jr. and A.D. Rudzik, *J. Med. Chem.*, **17**, 293 (1974).
- 3) G.A. Archer and L.H. Sternbach, *J. Org. Chem.*, **29**, 231 (1964); J.P. Maffrand, G. Ferrand, and F. Eloy, *Tetrahedron Lett.*, **1973**, 3449.
- 4) S. Farber, H.M. Wuest, and R.I. Meltzer, *J. Med. Chem.*, **7**, 235 (1964).
- 5) E.A. Swinyard, W.C. Brown, and L.S. Goodman, *J. Pharmacol. Exp. Ther.*, **106**, 319 (1952) and references cited therein; R.E. Tedeschi, D.H. Tedeschi, A. Mucha, L. Cook, P.A. Mattis, and E.J. Fellows, *J. Pharmacol. Exp. Ther.*, **125**, 28 (1959) and references cited therein.
- 6) All melting points were measured on a Thomas Hoover capillary melting point apparatus and are uncorrected.
- 7) a) A.J. Hill and D.T. Keach, *J. Am. Chem. Soc.*, **48**, 257 (1926); b) R.C. Tallman, *ibid.*, **56**, 126 (1934).
- 8) R.I. Fryer and A. Walser, Ger. Patent Offen. 2540522 (1976) [*C.A.*, **85**, 21497n (1976)].